WALTHAM, Mass., May 2, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has successfully submitted the Investigational Device Exemption (“IDE”) to the U.S. Food and Drug Administration (“FDA”) regarding its photorefractive keratectomy (“PRK”) pivotal study. The review process takes 30 days, at which point the FDA will allow the Company to initiate enrollment or will provide comments to be addressed.
Stephen From, CEO of EyeGate, said, “Following the strength of our data in the PRK pilot study, the FDA recommended that we are ready to commence a pivotal study, which if successful, will allow us to file a de novo submission. As we wait to hear back from the FDA, we will continue with the initiation of our pivotal study.”
About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company focused on
developing and commercializing products using its two proprietary platform
technologies for treating diseases and disorders of the eye.
EyeGate’s OBG platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries including surgical trauma.
EGP-437, EyeGate’s other product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System. For more information, please visit www.EyeGatePharma.com.
EyeGate Social
Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page
(https://www.facebook.com/ EyeGatePharma/), corporate Twitter account
(https://twitter.com/EyeGatePharma), and LinkedIn page (https://www.linkedin.com/company/135892/)
as channels of distribution of information about EyeGate and its product
candidates. Such information may be deemed material information, and EyeGate
may use these channels to comply with its disclosure obligations under Regulation
FD. Therefore, investors should monitor EyeGate’s website and its social media
accounts in addition to following its press releases, SEC filings, public
conference calls, and webcasts. The social media channels that EyeGate intends
to use as a means of disclosing the information described above may be updated
from time to time as listed on EyeGate’s investor relations website.
Forward-Looking
Statements
Some of the statements in this press release are “forward-looking” and are made
pursuant to the safe harbor provision of the Private Securities Litigation
Reform Act of 1995. These “forward-looking” statements include statements
relating to, among other things, the commercialization efforts and other
regulatory or marketing approval efforts pertaining to EyeGate’s products,
including EyeGate’s OBG product, its EGP-437 Combination Product, as well as
the success thereof, with such approvals or success may not be obtained or
achieved on a timely basis or at all. These statements involve risks and uncertainties
that may cause results to differ materially from the statements set forth in
this press release, including, among other things, certain risk factors
described under the heading “Risk Factors” contained in EyeGate’s Annual Report
on Form 10-K filed with the SEC on March 1, 2019 or described in EyeGate’s
other public filings. EyeGate’s results may also be affected by factors of
which EyeGate is not currently aware. The forward-looking statements in this
press release speak only as of the date of this press release. EyeGate
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to such statements to reflect any change in its
expectations with regard thereto or any changes in the events, conditions or
circumstances on which any such statement is based.
Contact
Joseph Green / Laine Yonker
Edison Advisors for EyeGate Pharmaceuticals
646-653-7030 / 7035
jgreen@edisongroup.com / lyonker@edisongroup.com